May Health, a clinical-stage medical device company dedicated to addressing polycystic ovary syndrome (PCOS), has announced the successful closure of a $25 million Series B financing round. The funding round was co-led by Bpifrance and Trill Impact Ventures, with participation from existing investor Sofinnova Partners, as well as Avestria Ventures and Kidron Capital Assets. PCOS affects approximately 10% of women globally, causing hormonal imbalances that can lead to a range of symptoms, including infertility. Despite its prevalence, effective treatment options for PCOS remain limited, prompting May Health’s pursuit of innovative solutions.
Related: CereVasc gets $70M financing to advance its eShunt® System
“For the millions of women living with PCOS, the physical and emotional impact of this condition is profound. From fertility challenges to emotional well-being and physical symptoms, women with PCOS need more viable treatment options,” said Anne Morrissey, CEO of May Health. “We are thankful to Bpifrance and Trill Impact for co-leading this financing round, together with our founding investor Sofinnova Partners, and to our deep bench of supporters and advisors for their confidence in our team and growth strategy. We are eager to continue building on the positive results of our previous clinical studies as well as this financing milestone as we work to become a leader in global women’s health and PCOS-related infertility.”
The centerpiece of May Health’s efforts is its Ovarian Rebalancing therapy, an investigational treatment designed to restore women’s natural ovulation cycles. The therapy involves a straightforward, one-time, in-office procedure utilizing radiofrequency (RF) energy to induce ovulation through targeted ablation of ovarian tissue.
“May Health is charting a new path in fertility care for women with PCOS with its innovative Ovarian Rebalancing therapy,” said Jean-François Morin, investment director at Bpifrance. “We are thrilled to support the company’s effort to bring its new approach to women with PCOS, including advancing it in the pivotal REBALANCE Study. With its unique mechanism of action, May Health’s device has the potential to significantly improve the lives of patients with PCOS, including but not limited to related infertility issues. We are committed to supporting May Health to become a leader in the PCOS space.”
Nina Rawal, co-head and partner at Trill Impact Ventures, added, “We see May Health as a great example of a company where commercial opportunity and impact go hand in hand. Trill Impact is excited to collaborate with the May Health team and its strong shareholders to bring their innovative product to women who have suffered from a lack of treatment options for too long.”
“For years, women with PCOS who struggle with infertility have sought alternative treatment options that go beyond IVF and laparoscopic ovarian drilling,” said Dr. Robert Auerbach, OBGYN, chairman of the May Health board. “Our team is working to develop a simple and safe procedure that can activate natural ovulation and help women regain their ability to grow their families. We’re thankful to our investment partners for their support and look forward to further research of Ovarian Balancing in the REBALANCE Study.”
The fresh funds from the Series B financing round will be used to support May Health’s growth and advance its Ovarian Rebalancing therapy through the pivotal REBALANCE Study. The study aims to evaluate the therapy’s effectiveness in addressing PCOS-related infertility and will involve more than 15 fertility centers across the United States.
